KR900013961A - 기억력 및 학습력 증강 또는 인식 또는 정신장해 치료용 d-시클로세린 및 d-알라닌 함유 조성물 - Google Patents

기억력 및 학습력 증강 또는 인식 또는 정신장해 치료용 d-시클로세린 및 d-알라닌 함유 조성물 Download PDF

Info

Publication number
KR900013961A
KR900013961A KR1019900003482A KR900003482A KR900013961A KR 900013961 A KR900013961 A KR 900013961A KR 1019900003482 A KR1019900003482 A KR 1019900003482A KR 900003482 A KR900003482 A KR 900003482A KR 900013961 A KR900013961 A KR 900013961A
Authority
KR
South Korea
Prior art keywords
therapeutically effective
effective amount
alanine
cycloserine
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019900003482A
Other languages
English (en)
Korean (ko)
Inventor
에이.코르디 알렉시스
알.잔스 미카엘
Original Assignee
파울 디. 마투카이티스
지.디.썰 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파울 디. 마투카이티스, 지.디.썰 앤드 캄파니 filed Critical 파울 디. 마투카이티스
Publication of KR900013961A publication Critical patent/KR900013961A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1019900003482A 1989-03-15 1990-03-15 기억력 및 학습력 증강 또는 인식 또는 정신장해 치료용 d-시클로세린 및 d-알라닌 함유 조성물 Ceased KR900013961A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32427989A 1989-03-15 1989-03-15
US324,279 1989-03-25
US473,241 1990-02-06
US07/473,241 US5061721A (en) 1989-03-15 1990-02-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Publications (1)

Publication Number Publication Date
KR900013961A true KR900013961A (ko) 1990-10-22

Family

ID=26984373

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900003482A Ceased KR900013961A (ko) 1989-03-15 1990-03-15 기억력 및 학습력 증강 또는 인식 또는 정신장해 치료용 d-시클로세린 및 d-알라닌 함유 조성물

Country Status (17)

Country Link
US (1) US5061721A (cg-RX-API-DMAC7.html)
EP (1) EP0387867B1 (cg-RX-API-DMAC7.html)
JP (1) JP2963720B2 (cg-RX-API-DMAC7.html)
KR (1) KR900013961A (cg-RX-API-DMAC7.html)
AT (1) ATE88890T1 (cg-RX-API-DMAC7.html)
AU (1) AU624917B2 (cg-RX-API-DMAC7.html)
CA (1) CA2010635C (cg-RX-API-DMAC7.html)
DE (1) DE69001503T2 (cg-RX-API-DMAC7.html)
DK (1) DK0387867T3 (cg-RX-API-DMAC7.html)
ES (1) ES2055197T3 (cg-RX-API-DMAC7.html)
FI (1) FI901289A7 (cg-RX-API-DMAC7.html)
GR (1) GR3008225T3 (cg-RX-API-DMAC7.html)
IE (1) IE64130B1 (cg-RX-API-DMAC7.html)
IL (1) IL93562A (cg-RX-API-DMAC7.html)
NO (1) NO901198L (cg-RX-API-DMAC7.html)
NZ (1) NZ232809A (cg-RX-API-DMAC7.html)
PT (1) PT93424B (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア ルイザ Nmda受容体のアロステリックモジュレーター
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
EP0691844A1 (en) * 1993-03-29 1996-01-17 Queen's University At Kingston Method for treating amyloidosis
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
AU4019395A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
JP2002513380A (ja) 1996-07-22 2002-05-08 コグネティックス・インコーポレイテッド コナントキンの使用
US6515103B1 (en) 1996-07-22 2003-02-04 University Of Utah Research Foundation Conantokins
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
ATE519485T1 (de) * 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
CN1527813A (zh) 2001-04-02 2004-09-08 О 作为治疗剂的抗氧化剂硝基氧和亚硝氮碳基
WO2002087423A2 (en) * 2001-05-02 2002-11-07 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
US20050176826A1 (en) * 2002-03-15 2005-08-11 H. Lundbeck A/S Use of asc-1 inhibitors to treat neurological and psychiatric disorders
UA80055C2 (en) * 2003-05-27 2007-08-10 Forest Laboratories Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
EP1660634A4 (en) * 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
KR20070007276A (ko) 2003-12-29 2007-01-15 제이슨 맥데빗 재발성 의학적 증상을 치료하기 위한 조성물 및 방법
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1836161B1 (en) 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
US20100113453A1 (en) * 2007-04-10 2010-05-06 Mcdevitt Jason P Sublingual Formulations of D-Cycloserine and Methods of Using Same
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
SG10201501050RA (en) 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
JP5689026B2 (ja) * 2010-06-17 2015-03-25 株式会社 資生堂 水中油型乳化皮膚化粧料
US9789093B2 (en) * 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
US9737562B2 (en) 2012-12-11 2017-08-22 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201505937SA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
JP6419087B2 (ja) 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系nmda受容体モジュレーターおよびその使用
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
JP2019527235A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタム及びビス−スピロ−ラクタムnmda受容体修飾因子及びその使用
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
CN109890825B (zh) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
KR102287477B1 (ko) * 2019-11-27 2021-08-09 (주)뉴로라이브 우울증 치료를 위한 사이클로세린 및 리튬 병용 요법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428730A (en) * 1967-06-30 1969-02-18 Hamao Umezawa Antibacterial mixture of o-carbamyl-d-serine and d-4-amino-3-isoxazolidone
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Also Published As

Publication number Publication date
EP0387867A1 (en) 1990-09-19
PT93424B (pt) 1996-08-30
ATE88890T1 (de) 1993-05-15
IL93562A (en) 1996-01-31
DE69001503T2 (de) 1993-09-09
AU624917B2 (en) 1992-06-25
CA2010635A1 (en) 1990-09-15
FI901289A0 (fi) 1990-03-15
NO901198D0 (no) 1990-03-14
NZ232809A (en) 1992-05-26
PT93424A (pt) 1990-11-07
FI901289A7 (fi) 1990-09-16
IE64130B1 (en) 1995-07-12
US5061721A (en) 1991-10-29
GR3008225T3 (cg-RX-API-DMAC7.html) 1993-09-30
EP0387867B1 (en) 1993-05-05
JP2963720B2 (ja) 1999-10-18
NO901198L (no) 1990-09-17
DK0387867T3 (da) 1993-06-01
IL93562A0 (en) 1990-11-29
JPH03148221A (ja) 1991-06-25
DE69001503D1 (de) 1993-06-09
CA2010635C (en) 2001-03-06
IE900921L (en) 1990-09-15
AU5073490A (en) 1990-09-20
ES2055197T3 (es) 1994-08-16

Similar Documents

Publication Publication Date Title
ATE419858T1 (de) Krillextrakte zur prävention und/oder behandlung von herz-kreislauf-erkrankungen
ATE219674T1 (de) Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
CA2339221A1 (en) Extracts of feverfew (tanacetum parthenium) against inflammatory disorders
DE69533940D1 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE270111T1 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
RU94002133A (ru) 6-хлор-5-фтор-3-(2-теноил)-2-оксиндол-1-карбоксамид как аналгезирующее и противовоспалительное средство
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
RU94037555A (ru) Железосодержащая композиция для предотвращения анемии, способ ее изготовления и способ лечения анемии
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
IL101675A (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
RU93048600A (ru) Натуральный поливитаминный комплекс "леветон"
RU95102611A (ru) Способ лечения туберкулеза легких
KR880004810A (ko) 소화성 궤양 치료제
PE20040932A1 (es) Metodo de mejora de la circulacion sanguinea
KR890015746A (ko) 메게스트롤 아세테이트로 aids 악액질을 치료하는 방법
KR900017599A (ko) 종양 치료용 약학 조성물
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний
RU93018067A (ru) Способ лечения кавернозной формы туберкулеза
RU95122262A (ru) Способ лечения повреждений периферических нервов при травмах конечностей
RU95102346A (ru) Способ лечения дисциркуляторной энцефалопатии

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900315

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950315

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19900315

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980213

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19980506

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19980213

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I